Lilly pill cuts body weight by 12.4% in trial, lagging Novo's Wegovy injection

Eli Lilly's experimental oral GLP-1 drug, orforglipron, demonstrated a 12.4% body weight reduction in a late-stage trial, which, while significant, lagged the 14.9-15% achieved by Novo Nordisk's injectable Wegovy and missed high investor expectations. This led to a nearly 15% plunge in Lilly's shares, erasing over $100 billion in market value, while Novo Nordisk shares gained. Despite the efficacy difference and some reported side effects, Lilly highlighted the pill's oral convenience, ease of manufacturing, and potential for broad market adoption due to patient preference and additional cardiovascular benefits, with analysts maintaining forecasts for substantial long-term sales.

Analysis

Eli Lilly's (LLY) experimental oral GLP-1 drug, orforglipron, demonstrated a 12.4% body weight reduction in a late-stage trial, a figure that, while clinically meaningful, fell short of high investor expectations and lagged the 14.9% efficacy of Novo Nordisk's (NVO) injectable Wegovy. This disappointment triggered a severe market reaction, with Lilly's shares plummeting nearly 15%—the steepest single-day drop in 25 years—while Novo Nordisk's stock gained over 6%. Despite the negative reception, Lilly's management highlighted the strategic value of an oral formulation, emphasizing its manufacturing simplicity and patient convenience over injections. However, the drug's tolerability profile presents a concern, with 33.7% of high-dose patients experiencing nausea and a trial dropout rate of over 10% due to adverse effects. Positively, orforglipron showed benefits in reducing cardiovascular risk markers, which is critical for securing insurance coverage. While analysts view this outcome as a near-term competitive win for Novo Nordisk, the long-term outlook for orforglipron remains significant, with Morgan Stanley forecasting potential sales of $40 billion by 2033 within a total obesity market expected to reach $150 billion.

Key Decisions for Investors

• Investors should reassess Eli Lilly's valuation following the historic stock drop, weighing whether the market has overly penalized the 12.4% efficacy data while undervaluing the strategic advantages of an oral formulation and pre-emptive manufacturing.
• The trial outcome strengthens Novo Nordisk's near-term competitive moat, and investors should monitor the progress of Novo's own high-efficacy oral drug, which could further entrench its dominance in the obesity market.
• Key factors to monitor before adjusting positions include the full trial data, particularly the tolerability profile, and future announcements on pricing and insurance coverage, as these will heavily influence orforglipron's commercial viability against injectable and rival oral treatments.